Press Resease

Anticoagulants Market by Drug Class (NOACs, Heparin & LMWH, Vitamin K Antagonist, and Others), by Route of Administration (Injectable Anticoagulant and Oral Anticoagulant), and by Application (Stroke, Atrial Fibrillation, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 15-Mar-2019 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-3920 Status : Published

Global anticoagulants market expected to generate around USD 43.6 billion by 2025, at a CAGR of around 7.7% between 2019 and 2025. Anticoagulants reduce or prevent blood coagulation and delay clotting time. Anticoagulants are prescribed to people who are at a higher risk of developing blood clots.

Description

The report covers a forecast and an analysis of the anticoagulants market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes drivers and restraints of the anticoagulants market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the anticoagulants market on a global and regional level.

In order to give the users of this report a comprehensive view of the anticoagulants market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Anticoagulants Market

The report provides company market share analysis to give a broader overview of the key players in the anticoagulants market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the anticoagulants market on a global and regional basis.

The study provides a decisive view of the anticoagulants market based on drug class, route of administration, application, and region. By drug class, the anticoagulants market is segmented into NOACs, heparin and LMWH, vitamin K antagonist, and others. The NOACs is sub-segmented into bevyxxa, eliquis, lixiana and savaysa, pradaxa, and xarelto. The route of administration segment is divided into injectable anticoagulant and oral anticoagulant. The application segment is segmented into stroke, atrial fibrillation, pulmonary embolism (PE), deep vein thrombosis (DVT), and others.

The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further fragmented into major countries including the U.S., Germany, France, UK, China, Japan, India, and Brazil.

Some players of the global anticoagulants market are Bayer AG, Aspen Holdings, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, GlaxoSmithKline, Pfizer, Inc., Sanofi S.A., Johnson & Johnson, and Portola Pharmaceuticals, Inc., among others.

This report segments the global anticoagulants market as follows:

Global Anticoagulants Market: By Drug Class

  • NOACs
    • Bevyxxa
    • Eliquis
    • Lixiana and Savaysa
    • Pradaxa
    • Xarelto
  • Heparin and LMWH
  • Vitamin K Antagonist
  • Others

Global Anticoagulants Market: By Route of Administration

  • Injectable Anticoagulant
  • Oral Anticoagulant

Global Anticoagulants Market: By Application

  • Stroke
  • Atrial Fibrillation
  • Pulmonary Embolism (PE)
  • Deep vein thrombosis (DVT)
  • Others

Global Anticoagulants Market: By Region

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Anticoagulants market, 2016-2025 (USD Billion)
    • 2.2. Global Anticoagulants market: Snapshot
  •  
  • Chapter 3. Anticoagulants Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Growing incidences of cardiovascular disorders and venous thromboembolism (VTE)
      • 3.2.2. The increasing acceptance of novel oral anticoagulants (NOACs)
    • 3.3. Market Restraints
      • 3.3.1. The higher rate of NOACs
      • 3.3.2. The existence of alternative drugs
    • 3.4. Opportunities
      • 3.4.1. Increasing investment by the leading market players
      • 3.4.2. High unmet needs
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Drug Class
      • 3.6.2. Market attractiveness analysis, by Route of Administration
      • 3.6.3. Market attractiveness analysis, by Application
      • 3.6.4. Market attractiveness analysis, by Region
  •  
  • Chapter 4. Global Anticoagulants market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Anticoagulants market: company market share, 2018
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures
      • 4.2.4. Research and Development and Regional Expansion
  •  
  • Chapter 5. Global Anticoagulants market - Drug Class Analysis
    • 5.1. Global Anticoagulants market: Drug Class overview
      • 5.1.1. Global Anticoagulants market revenue share, by Drug Class, 2018 and 2025
    • 5.2. NOACs
      • 5.2.1. Global Anticoagulants market for NOACs, 2016-2025 (USD Billion)
    • 5.3. Heparin & LMWH
      • 5.3.1. Global Anticoagulants market for Heparin & LMWH, 2016-2025 (USD Billion)
    • 5.4. Vitamin K Antagonist
      • 5.4.1. Global Anticoagulants market for Vitamin K Antagonist, 2016-2025 (USD Billion)
    • 5.5. Others
      • 5.5.1. Global Anticoagulants market for Others, 2016-2025 (USD Billion)
  •  
  • Chapter 6. Global Anticoagulants market - Route of Administration Analysis
    • 6.1. Global Anticoagulants market: Route of Administration overview
      • 6.1.1. Global Anticoagulants market revenue share, by Route of Administration, 2018 and 2025
    • 6.2. Injectable Anticoagulant
      • 6.2.1. Global Anticoagulants market for Injectable Anticoagulant, 2016-2025 (USD Billion)
    • 6.3. Oral Anticoagulant
      • 6.3.1. Global Anticoagulants market for Oral Anticoagulant, 2016-2025 (USD Billion)
  •  
  • Chapter 7. Global Anticoagulants market - Application Analysis
    • 7.1. Global Anticoagulants market: Application overview
      • 7.1.1. Global Anticoagulants market revenue share, by Application, 2018 and 2025
    • 7.2. Stroke
      • 7.2.1. Global Anticoagulants market for Stroke, 2016-2025 (USD Billion)
    • 7.3. Atrial Fibrillation
      • 7.3.1. Global Anticoagulants market for Atrial Fibrillation, 2016-2025 (USD Billion)
    • 7.4. Pulmonary Embolism (PE)
      • 7.4.1. Global Anticoagulants market for Pulmonary Embolism (PE), 2016-2025 (USD Billion)
    • 7.5. Deep vein thrombosis (DVT)
      • 7.5.1. Global Anticoagulants market for Deep vein thrombosis (DVT), 2016-2025 (USD Billion)
    • 7.6. Others
      • 7.6.1. Global Anticoagulants market for Others, 2016-2025 (USD Billion)
  •  
  • Chapter 8. Global Anticoagulants market - Regional Analysis
    • 8.1. Global Anticoagulants market: Regional overview
      • 8.1.1. Global Anticoagulants market revenue share, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
      • 8.2.2. North America Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
      • 8.2.3. North America Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
      • 8.2.4. The U.S.
        • 8.2.4.1. The U.S. Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 8.2.4.2. The U.S. Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
        • 8.2.4.3. The U.S. Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
      • 8.2.5. Rest of North America
        • 8.2.5.1. Rest of North America Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 8.2.5.2. Rest of North America Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
        • 8.2.5.3. Rest of North America Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
    • 8.3. Europe
      • 8.3.1. Europe Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
      • 8.3.2. Europe Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
      • 8.3.3. Europe Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
      • 8.3.4. Germany
        • 8.3.4.1. Germany Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 8.3.4.2. Germany Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
        • 8.3.4.3. Germany Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
      • 8.3.5. U.K.
        • 8.3.5.1. U.K. Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 8.3.5.2. U.K. Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
        • 8.3.5.3. U.K. Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
      • 8.3.6. France
        • 8.3.6.1. France Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 8.3.6.2. France Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
        • 8.3.6.3. France Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
      • 8.3.7. Rest of Europe
        • 8.3.7.1. Rest of Europe Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 8.3.7.2. Rest of Europe Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
        • 8.3.7.3. Rest of Europe Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
      • 8.4.2. Asia Pacific Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
      • 8.4.3. Asia Pacific Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
      • 8.4.4. China
        • 8.4.4.1. China Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 8.4.4.2. China Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
        • 8.4.4.3. China Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 8.4.5.2. Japan Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
        • 8.4.5.3. Japan Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
      • 8.4.6. India
        • 8.4.6.1. India Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 8.4.6.2. India Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
        • 8.4.6.3. India Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
      • 8.4.7. Rest of Asia Pacific
        • 8.4.7.1. Rest of Asia Pacific Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 8.4.7.2. Rest of Asia Pacific Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
        • 8.4.7.3. Rest of Asia Pacific Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
    • 8.5. Latin America
      • 8.5.1. Latin America Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
      • 8.5.2. Latin America Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
      • 8.5.3. Latin America Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 8.5.4.2. Brazil Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
        • 8.5.4.3. Brazil Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
        • 8.5.5.2. Rest of Latin America Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
        • 8.5.5.3. Rest of Latin America Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Anticoagulants market revenue, by Drug Class, 2016-2025 (USD Billion)
      • 8.6.2. The Middle East and Africa Anticoagulants market revenue, by Route of Administration, 2016-2025 (USD Billion)
      • 8.6.3. The Middle East and Africa Anticoagulants market revenue, by Application, 2016-2025 (USD Billion)
  •  
  • Chapter 9. Company Profile
    • 9.1. Bayer AG
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. Aspen Holdings
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. Boehringer Ingelheim GmbH
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. Daiichi Sankyo Company, Limited
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. Bristol-Myers Squibb Company
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. GlaxoSmithKline
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. Pfizer, Inc.
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. Sanofi S.A.
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Product portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. Johnson & Johnson
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Product portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. Portola Pharmaceuticals, Inc.
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Product portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments

Methodology

Free Analysis

Anticoagulant medicines help in preventing blood clots and are prescribed to people who are at a higher risk of getting clots. Anticoagulant decreases their probabilities of developing severe conditions like heart attacks and strokes. Anticoagulants interrupt the process of blood clot formation, which are also referred to as blood-thinning medicines. If a blood clot restricts the movement of blood over a blood vessel, the afflicted part will cease to work properly. Clot formation could lead to serious medical conditions, such as strokes, deep vein thrombosis (DVT), heart attacks, and pulmonary embolism (PE). The most popular types of anticoagulants are novel oral anticoagulants (NOACs), Vitamin K antagonist, and Low-molecular-weight heparin (LMWH). Novel oral anticoagulants (NOACs) have gained immense popularity in recent years due to their multiple benefits. Vitamin K antagonists are prescribed for prolonged anticoagulation therapy. Low-molecular-weight heparin (LMWH) enables outpatient management of disorders, such as pulmonary embolism, deep vein thrombosis, etc.

The growing incidences of cardiovascular disorders, chronic diseases, and venous thromboembolism (VTE), increasing acceptance of novel oral anticoagulants (NOACs), growing awareness regarding the use of NOACs, escalating aging population, dearth of precise substitutes for anticoagulant drugs, advantageous government policies, and rising number of obese people will act as major driving factors of the global anticoagulants market. Increasing investments made by leading market players for developing novel products and offer solutions for high unmet patient needs will create new growth opportunities for the market players in the anticoagulants market. Nevertheless, the high cost of NOACs, the existence of alternative drugs, stringent government regulations, side-effect risks, and complications related to the use of oral anticoagulants may restrict the global anticoagulants market.

Global Anticoagulants Market

The global anticoagulants market is segmented based on drug class, route of administration, and application. By drug class, the anticoagulants market is segmented into NOACs, heparin and LMWH, vitamin K antagonist, and others. The NOACs is sub-segmented into bevyxxa, eliquis, lixiana and savaysa, pradaxa, and xarelto. The route of administration segment is divided into injectable anticoagulant and oral anticoagulant. The application segment is segmented into the stroke, atrial fibrillation, pulmonary embolism (PE), deep vein thrombosis (DVT), and others.

By region, North America will lead the global anticoagulants market over the forecast time period, owing to the presence of state-of-the-art healthcare setup, high demand for innovative therapeutics, huge target population, existence of trained healthcare professionals, and rising incidences of cardiovascular disorders. Europe will be the second largest market for anticoagulants in the years ahead, due to the escalating aging population, rising occurrences of chronic diseases, advantageous government policies, and the rising number of obese people. The Asia Pacific will propagate at a speedy rate over the forecast time period, owing to the huge population, growing number of people suffering from chronic disorders, such as cancer, diabetes, and cardiovascular diseases, promising government policies, and growing investments made by pharmaceutical companies for research and development.

Some players of the global anticoagulants market are Bayer AG, Aspen Holdings, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, GlaxoSmithKline, Pfizer, Inc., Sanofi S.A., Johnson & Johnson, and Portola Pharmaceuticals, Inc., among others.

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com